Lee's Pharmaceutical Holdings Limited (HK:0950)
:0950
Top Page
Lee's Pharmaceutical Holdings Limited
(0950)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$1.50
▼(-3.23% Downside)
Action:ReiteratedDate:11/22/25
The overall stock score is primarily influenced by the company's solid financial performance and attractive valuation. However, the bearish technical indicators suggest caution in the short term. The absence of earnings call insights and corporate events limits additional context.
Positive Factors
Cash Generation
Sustained FCF growth of 24.27% TTM indicates improving cash conversion that supports durable needs: R&D funding, commercial scale-up, dividend or buybacks, and selective M&A. Strong FCF reduces reliance on external financing and improves resilience through cyclical downturns.
Negative Factors
Return on Equity
ROE around 5.4% signals limited returns on invested capital versus typical growth-stage biotech expectations. Persistently modest ROE can reflect slow commercialization traction, suboptimal pricing or capital allocation, constraining long-term shareholder value creation absent operational improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation
Sustained FCF growth of 24.27% TTM indicates improving cash conversion that supports durable needs: R&D funding, commercial scale-up, dividend or buybacks, and selective M&A. Strong FCF reduces reliance on external financing and improves resilience through cyclical downturns.
Read all positive factors
Lee's Pharmaceutical Holdings Limited (0950) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$730.16M
Dividend Yield2.92%
Average Volume (3M)5.40M
Price to Earnings (P/E)6.3
Beta (1Y)0.66
Revenue Growth19.80%
EPS Growth55.09%
CountryHK
Employees1,022
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.04
Shares Outstanding588,835,300
10 Day Avg. Volume4,101,801
30 Day Avg. Volume5,400,283
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.51
Price to Sales (P/S)0.60
P/FCF Ratio24.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lee's Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovas...
How the Company Makes Money
Lee's Pharmaceutical generates revenue primarily through the sale of its pharmaceutical products, which include both proprietary drugs and generic medications. The company has a diversified revenue model that includes direct sales to healthcare pr...
Lee's Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
75
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.44B | 1.40B | 1.05B | 1.23B | 1.27B | 1.22B |
| Gross Profit | 762.81M | 753.36M | 551.31M | 770.75M | 806.28M | 781.07M |
| EBITDA | 263.90M | 260.87M | 193.05M | 229.06M | 2.13B | 279.43M |
| Net Income | 97.81M | 93.10M | 16.70M | 51.28M | 1.99B | 129.32M |
Balance Sheet | ||||||
| Total Assets | 3.00B | 2.62B | 2.89B | 2.78B | 3.64B | 3.25B |
| Cash, Cash Equivalents and Short-Term Investments | 303.58M | 216.84M | 171.00M | 189.30M | 277.53M | 414.54M |
| Total Debt | 243.63M | 227.30M | 204.14M | 163.49M | 267.14M | 156.71M |
| Total Liabilities | 1.17B | 1.07B | 930.07M | 939.50M | 1.25B | 1.14B |
| Stockholders Equity | 1.94B | 1.65B | 2.04B | 1.92B | 2.46B | 2.15B |
Cash Flow | ||||||
| Free Cash Flow | 324.98M | 34.45M | -49.63M | 69.81M | -160.04M | -139.23M |
| Operating Cash Flow | 367.35M | 242.01M | 110.08M | 283.63M | 210.68M | 218.91M |
| Investing Cash Flow | -211.36M | -190.23M | -145.22M | -256.05M | -370.28M | -523.74M |
| Financing Cash Flow | -35.65M | -1.96M | 13.44M | -128.60M | 60.97M | -9.80M |
Lee's Pharmaceutical Holdings Limited Technical Analysis
Negative
1.55
Price Trends
1.42
Negative
1.55
Negative
1.71
Negative
Market Momentum
-0.05
Positive
38.46
Neutral
31.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0950, the sentiment is Negative. The current price of 1.55 is above the 20-day moving average (MA) of 1.31, above the 50-day MA of 1.42, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 38.46 is Neutral, neither overbought nor oversold. The STOCH value of 31.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0950.
Lee's Pharmaceutical Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$7.15B | 6.31 | 10.84% | 5.80% | -20.64% | -25.39% | |
66 Neutral | HK$1.71B | 7.90 | 5.33% | 5.16% | 2.89% | -68.83% | |
64 Neutral | HK$730.16M | 6.31 | 5.44% | 2.92% | 19.80% | 55.09% | |
58 Neutral | HK$9.91B | 14.45 | 7.49% | 4.47% | 1.65% | -16.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$13.53B | 22.81 | -1.84% | 0.87% | 19.21% | -115.91% |
* Healthcare Sector Average
HK:0950
Lee's Pharmaceutical Holdings Limited
1.24
-0.12
-8.82%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.45
0.79
121.37%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.14
0.04
3.64%
HK:2877
China Shineway Pharmaceutical Group Limited
9.47
2.14
29.20%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.40
0.82
14.61%
Lee's Pharmaceutical Holdings Limited Corporate Events
Lee’s Pharm Wins FDA Clearance for U.S. ADASUVE Manufacturing Shift
Jan 27, 2026
Lee’s Pharmaceutical Holdings Limited has secured U.S. Food and Drug Administration approval for a supplemental new drug application relating to ADASUVE (loxapine) Inhalation Powder, authorising the move of the drug’s commercial manufa...
Lee’s Pharma Adds Financial Detail to Discloseable Asset Acquisition
Dec 22, 2025
Lee’s Pharmaceutical Holdings Limited has issued a supplemental announcement regarding its previously disclosed acquisition of certain assets, providing additional financial details on the purchased portfolio. The company reported that the a...
Lee’s Pharmaceutical Mourns Death of Senior Business Development Director Michele Dalla Libera
Dec 18, 2025
Lee’s Pharmaceutical Holdings Limited has announced the death of Michele Dalla Libera, its Senior Director of Business Development, on 15 December 2025. Dalla Libera was instrumental in the group’s evolution after its 2002 listing, lea...
Lee’s Pharmaceutical Acquires Alexza Business Assets for $15 Million
Dec 8, 2025
Lee’s Pharmaceutical Holdings Limited has announced a significant acquisition involving the purchase of assets related to the Alexza Business for US$15 million. This transaction, which involves intellectual property rights, inventories, and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.